504632 | PHCCC - CAS 1161205-27-1 - Calbiochem

504632
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₁₇H₁₄N₂O₃ 1161205-27-1

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      5.04632.0001
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 10 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA potent positive allosteric modulator selective for mGlu4 receptors (EC50 = 3 µM). Also, a less potent agonist of mGlu6 receptors (EC50 = 15 µM). Biologically active admitted systematically. Often used in assessing the functional roles of mGlu4 receptors or group III mGlu receptors in a variety of research areas, such as epileptic seizures, depression, addiction, anxiety and stress related disorders, analgesia, locomotion, neural plasticity, and Parkinson's disease.
          Catalogue Number504632
          Brand Family Calbiochem®
          Synonyms(E)-1,1a,7,7a-Tetrahydro-7-(hydroxyimino)-N-phenylcyclopropa[b]chromene-1a-carboxamide
          References
          ReferencesOh, H., et al. 2013. Psychopharmacol. 1, 9.
          Dickerson, W., 2012. Neurodegen. Diseases Manag. 2, 221.
          Le Poul, E., et al. 2012. J. Pharmacol. & Exp. Therap. 343, 167.
          Szczurowska, E., 2012. Physiol. Res. 61, 619.
          Beqollari, D., et al. 2008. Eur. J. Pharmacol. 589, 4.
          Niswender, M., et al. 2008. Mol. Pharmacol. 74, 1345.
          Stachowicz, K., et al. 2004. Eur. J. Pharmacol. 498, 153.
          Maj, M., et al. 2003. Neuropharmacol. 45, 895.
          Marino, J., et al. 2003. PNAS. 100, 13668.
          Product Information
          CAS number1161205-27-1
          FormWhite solid
          Hill FormulaC₁₇H₁₄N₂O₃
          Chemical formulaC₁₇H₁₄N₂O₃
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetmGlu₄ receptors
          Purity≥98% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          References

          Reference overview
          Oh, H., et al. 2013. Psychopharmacol. 1, 9.
          Dickerson, W., 2012. Neurodegen. Diseases Manag. 2, 221.
          Le Poul, E., et al. 2012. J. Pharmacol. & Exp. Therap. 343, 167.
          Szczurowska, E., 2012. Physiol. Res. 61, 619.
          Beqollari, D., et al. 2008. Eur. J. Pharmacol. 589, 4.
          Niswender, M., et al. 2008. Mol. Pharmacol. 74, 1345.
          Stachowicz, K., et al. 2004. Eur. J. Pharmacol. 498, 153.
          Maj, M., et al. 2003. Neuropharmacol. 45, 895.
          Marino, J., et al. 2003. PNAS. 100, 13668.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision12-July-2013 JSW
          Synonyms(E)-1,1a,7,7a-Tetrahydro-7-(hydroxyimino)-N-phenylcyclopropa[b]chromene-1a-carboxamide
          DescriptionA potent positive allosteric modulator selective for mGlu4 receptors (EC50 = 3 µM). Also, a less potent agonist of mGlu6 receptors (EC50 = 15 µM). Biologically active admitted systematically. Often used in assessing the functional roles of mGlu4 receptors or group III mGlu receptors in a variety of research areas, such as epileptic seizures, depression, addiction, anxiety and stress related disorders, analgesia, locomotion, neural plasticity, and Parkinson's disease.
          FormWhite solid
          CAS number1161205-27-1
          Chemical formulaC₁₇H₁₄N₂O₃
          Structure formulaStructure formula
          Purity≥98% by HPLC
          SolubilityDMSO (100 mM)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesOh, H., et al. 2013. Psychopharmacol. 1, 9.
          Dickerson, W., 2012. Neurodegen. Diseases Manag. 2, 221.
          Le Poul, E., et al. 2012. J. Pharmacol. & Exp. Therap. 343, 167.
          Szczurowska, E., 2012. Physiol. Res. 61, 619.
          Beqollari, D., et al. 2008. Eur. J. Pharmacol. 589, 4.
          Niswender, M., et al. 2008. Mol. Pharmacol. 74, 1345.
          Stachowicz, K., et al. 2004. Eur. J. Pharmacol. 498, 153.
          Maj, M., et al. 2003. Neuropharmacol. 45, 895.
          Marino, J., et al. 2003. PNAS. 100, 13668.